Informing selection of drugs for COVID-19 treatment through adverse events analysis

Coronavirus disease 2019 (COVID-19) is an ongoing pandemic and there is an urgent need for safe and effective drugs for COVID-19 treatment. Since developing a new drug is time consuming, many approved or investigational drugs have been repurposed for COVID-19 treatment in clinical trials. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Wenjing, Pan, Bohu, Sakkiah, Sugunadevi, Ji, Zuowei, Yavas, Gokhan, Lu, Yanhui, Komatsu, Takashi E., Lal-Nag, Madhu, Tong, Weida, Patterson, Tucker A., Hong, Huixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263777/
https://www.ncbi.nlm.nih.gov/pubmed/34234253
http://dx.doi.org/10.1038/s41598-021-93500-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263777/
https://www.ncbi.nlm.nih.gov/pubmed/34234253
http://dx.doi.org/10.1038/s41598-021-93500-5

Ejemplares similares